logo
Man who let snakes bite him 200 times spurs new antivenom hope

Man who let snakes bite him 200 times spurs new antivenom hope

Yahoo08-06-2025
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
dl/giv
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jake Paul Calls Out Dana White Over Fighter's Health Emergency: ‘Where's the Help?'
Jake Paul Calls Out Dana White Over Fighter's Health Emergency: ‘Where's the Help?'

Yahoo

time26 minutes ago

  • Yahoo

Jake Paul Calls Out Dana White Over Fighter's Health Emergency: ‘Where's the Help?'

Jake Paul Calls Out Dana White Over Fighter's Health Emergency: 'Where's the Help?' originally appeared on Athlon Sports. Jake Paul walked out of Anaheim, California, with another victory under his belt this past Saturday, earning a unanimous decision win over the battle-tested Julio César Chávez Jr. The bout marked another milestone in Paul's evolving boxing career—but it was what happened after the fight that left a deeper impression. Advertisement Jake Paul Getty Images At the post-fight press conference, Paul ditched the usual victory lap and turned his energy toward something far heavier: a former rival in desperate need of help. After the win, Paul stepped to the mic and surprised the crowd: 'Say a prayer for Ben Askren and his family,' he said, with a tone that felt more personal than promotional. Paul didn't sugarcoat it, in a moment also captured by MMA Junkie: 'None of these people like Dana (White) are stepping in, so I feel like I have to do something.' Ben Askren is now facing a critical health crisis that has stunned much of the combat sports world. He's in need of a double lung transplant—a procedure typically reserved for patients with severe, end-stage respiratory failure. According to Jake Paul, Askren's insurance claim for the transplant was denied, leaving him in a dire situation without proper medical support. Paul has pledged financial help and is calling on others in the MMA community to rally behind a fighter once known for his toughness, now battling for his life. Advertisement Love or hate Jake Paul, Saturday night was a reminder that sometimes the loudest voices are the ones willing to speak up when it actually matters. Related: 'He Needs to Be Humbled' – Fans Slam Topuria's Premature Celebration Ahead of UFC 317 Related: 'He Can't Knock Me Out' – UFC Star Fires a Brutal Message at Topuria After UFC 317 This story was originally reported by Athlon Sports on Jun 29, 2025, where it first appeared.

Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients
Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients

Yahoo

time27 minutes ago

  • Yahoo

Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best NASDAQ growth stocks to buy for the next 3 years. On June 24, Corcept Therapeutics announced positive results from the CATALYST trial of Korlym (mifepristone). The data was presented at the American Diabetes Association's 85th Scientific Sessions and also published in Diabetes Care. It showed that Korlym improved glucose control in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. The trial met its primary endpoint, as patients receiving Korlym experienced a 1.47% decrease in HbA1c from baseline, as compared to a 0.15% decrease in the placebo group. Those on a 900mg dose saw a 2.01% HbA1c improvement. Beyond blood sugar, Korlym also led to reductions in body weight (by 5.1 kg) and waist circumference (by 5.1 cm), even as patients reduced or stopped other glucose-lowering medications. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. The CATALYST trial is the largest to date investigating hypercortisolism in difficult-to-control type 2 diabetes. Its initial phase screened 1,057 patients and found that 24% had hypercortisolism, which made them eligible for the treatment phase. Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Trump officials ‘secretly' changed US health data in ‘gender ideology' crackdown, researchers allege
Trump officials ‘secretly' changed US health data in ‘gender ideology' crackdown, researchers allege

Yahoo

time39 minutes ago

  • Yahoo

Trump officials ‘secretly' changed US health data in ‘gender ideology' crackdown, researchers allege

The Trump administration quietly altered massive US health datasets to remove any mention of gender, according to a new analysis. Scientists around the world rely on health data from US government agencies like the Centers for Disease Control and Prevention (CDC). But since President Donald Trump took office in January, these agencies have been altering data labels, mostly without disclosure, according to the investigation published in The Lancet, a leading medical journal. The authors argue that the 'hidden' changes could cast doubt on the integrity of American science. The database edits 'might be politically motivated and [are] not transparent,' Dr Aaron Kesselheim, a professor at Harvard Medical School, and Janet Freilich, a law professor at Boston University, said in the paper. Related Will Trump's funding cuts help Europe lure top research talent from the US? Their analysis included 232 US health datasets that were edited from late January to late March, covering veterans' health care use, global tobacco consumption, stroke deaths, nutrition, exercise, and obesity. It did not include datasets that are updated on a regular basis. About half of these datasets were 'substantially altered' during the two-month period, but only 15 acknowledged that changes had been made, the study found. The parts of the datasets meant for these disclosures remained empty as of early May, the researchers said. In most of the edited datasets – 106 of them – the word 'gender' was swapped out for 'sex'. Related US demands that EU companies comply with anti-diversity order US agencies have not confirmed or explained the changes, but Freilich and Kesselheim suspect they were made to comply with a Trump order to remove 'messages that promote or otherwise inculcate gender ideology'. The executive order, issued on Trump's first day in office, said it aimed to restore 'biological truth' to US agencies, and set a national policy 'to recognise two sexes, male and female,' they said. It was part of a flurry of activity to clamp down on LGBTQ protections. Some data was initially removed from federal websites, but was largely restored due to a court order. Related Trump administration's funding freeze for foreign medical research to hit European scientists The Lancet analysis indicates that not all changes were reversed. It is not clear if the actual numbers were altered, or only the labels about gender or sex. But Freilich and Kesselheim said the distinction is important because some people will respond to surveys differently based on each term. That can undermine the quality of the data and lead researchers to draw inaccurate conclusions, they said. They described the undisclosed changes as a 'crisis' that could make US data 'untrustworthy and unusable'. They called on governments elsewhere in the world to invest in other data sources.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store